Irish Standard Recommendation
S.R. CEN/TS 17390-2:2020

Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood - Part 2: Isolated DNA

S.R. CEN/TS 17390-2:2020

Incorporating amendments/corrigenda/National Annexes issued since publication:

The National Standards Authority of Ireland (NSAI) produces the following categories of formal documents:

I.S. xxx: Irish Standard — national specification based on the consensus of an expert panel and subject to public consultation.

S.R. xxx: Standard Recommendation — recommendation based on the consensus of an expert panel and subject to public consultation.

SWiFT xxx: A rapidly developed recommendatory document based on the consensus of the participants of an NSAI workshop.

This document replaces/revises/consolidates the NSAI adoption of the document(s) indicated on the CEN/CENELEC cover/Foreword and the following National document(s):

NOTE: The date of any NSAI previous adoption may not match the date of its original CEN/CENELEC document.

This document is based on:	*Published:*
CEN/TS 17390-2:2020	2020-01-22

This document was published under the authority of the NSAI and comes into effect on:	ICS number:
2020-02-09	11.100.10
	NOTE: If blank see CEN/CENELEC cover page

NSAI	T +353 1 807 3800	Sales:
1 Swift Square,	F +353 1 807 3838	T +353 1 857 6730
Northwood, Santry	E standards@nsai.ie	F +353 1 857 6729
Dublin 9	W NSAI.ie	W standards.ie

Údarás um Chaighdeáin Náisiúnta na hÉireann

National Foreword

S.R. CEN/TS 17390-2:2020 is the adopted Irish version of the European Document CEN/TS 17390-2:2020, Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood - Part 2: Isolated DNA

This document does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

For relationships with other publications refer to the NSAI web store.

Compliance with this document does not of itself confer immunity from legal obligations.

In line with international standards practice the decimal point is shown as a comma (,) throughout this document.

This page is intentionally left blank

TECHNICAL SPECIFICATION

SPÉCIFICATION TECHNIQUE

TECHNISCHE SPEZIFIKATION

CEN/TS 17390-2

January 2020

ICS 11.100.10

English Version

Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood - Part 2: Isolated DNA

Analyses de diagnostic moléculaire in vitro - Spécifications relatives aux processus préanalytiques pour les cellules tumorales circulantes (CTCs) dans le sang total veineux - Partie 2: ADN extrait

Molekularanalytische in vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für zirkulierende Tumorzellen (CTC) in venösen Vollblutproben - Teil 2: Isolierte DNA

This Technical Specification (CEN/TS) was approved by CEN on 27 October 2019 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.

EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Ref. No. CEN/TS 17390-2:2020 E

Contents

Page

European foreword

This document (CEN/TS 17390-2:2020) has been prepared by Technical Committee CEN/TC 140 “In vitro diagnostic medical devices”, the secretariat of which is held by DIN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

CEN/TS 17390 consists of the following parts, under the general title *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for Circulating Tumor Cells (CTCs) in venous whole blood*:

— Part 1: Isolated RNA

— Part 2: Isolated DNA

— Part 3: Preparations for analytical CTC staining

According to the CEN/CENELEC Internal Regulations, the national standards organisations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Introduction

Solid tumours release cells and bioanalytes into blood and other body fluids. This has opened the option of minimally-invasive tumour detection, diagnosis and characterization from venous whole blood (liquid biopsies). Liquid biopsies are expected to enable earlier detection and diagnosis of cancers and advance personalized patient treatment. These applications have become one of the fastest growing segments of the entire diagnostic market.

Circulating tumour cells (CTCs) in venous whole blood reflect the disease complexity that evolves during tumour progression, with distinct genetic, epigenetic and expression features. Beside the prognostic role of CTC identification and/or enumeration in cancer progression, CTC molecular characterization can improve e.g. disease outcome prediction, therapeutic guidance and post-treatment monitoring of the patient.

CTCs are now considered as a surrogate of tumour tissue in cancer early development, progression and metastatic phase.

Molecular characterization of CTCs can provide for example a strategy for monitoring cancer genotype during systemic therapies [1], identification of mechanisms of disease progression, identification of novel targets for biological treatment [2] and to select targeted therapies. Moreover, CTC single-cell sequencing is as an important tool for tumour genomic heterogeneity analysis [3] [4] [5]. Molecular examination techniques such as qPCR, dPCR and sequencing methods including next generation sequencing (NGS) enable to characterize CTC specific DNA features.

CTCs are fragile and tend to degrade within a few hours when collected in conventional blood collection tubes, e.g. EDTA containing tubes, without dedicated CTC stabilizers. CTCs are extremely rare, especially in early disease, e.g. less than 10 cells per 10 ml of blood, representing a ratio of approx. $1:10^7$ CTCs to white blood cells (WBCs). This low ratio represents a significant challenge to CTC enrichment required for examination. Furthermore, co-enrichment of normal blood cells causes a dilution of CTCs. The challenge is to minimize the amount of co-enriched WBCs for subsequent accurate and sensitive detection of CTC specific genetic and epigenetic alterations, especially when dealing with minor tumour cell clones.

Special measures need to be taken to get rid of the WBCs in order to obtain good quality DNA samples characterized by high purity and thus representative of the mutational pattern within the tumour.

Standardization of all steps of the pre-examination process is required. This includes blood collection and stabilization, transport, storage, CTC enrichment, CTC isolation (if required), and DNA isolation. An exemplary complete workflow for the molecular characterization of single CTCs is provided in Annex A. A decision guideline for the critical steps of the CTC pre-analytical workflow for DNA isolation is provided in Annex B.

This document describes special measures that need to be taken to obtain appropriate quality and quantity of DNA from CTC containing blood specimens for subsequent examination.

In this document, the following verbal forms are used:

— “shall” indicates a requirement;

— “should” indicates a recommendation;

— “may” indicates a permission;

— “can” indicates a possibility or a capability.

1 Scope

This document gives guidelines on the handling, storage, processing and documentation of venous whole blood specimens intended for the examination of human DNA isolated from circulating tumour cells (CTCs) during the pre-examination phase before a molecular examination is performed.

This document is applicable to molecular *in vitro* diagnostic examinations including laboratory developed tests performed by medical laboratories. It is also intended to be used by laboratory customers, *in vitro* diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities.

This document does not cover the isolation of genomic DNA directly from venous whole blood containing CTCs. This is covered in EN ISO 20186-2, *Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 2: Isolated genomic DNA*.

This document does not cover the isolation of specific white blood cells and subsequent isolation of genomic DNA therefrom.

This document does not cover pre-analytical workflow requirements for viable CTC cryopreservation and culturing.

NOTE 1 The requirements given in this document can also be applied to other circulating rare cells (e.g. foetal cells).

NOTE 2 International, national or regional regulations or requirements can also apply to specific topics covered in this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 15189:2012, *Medical laboratories - Requirements for quality and competence (ISO 15189:2012, Corrected version 2014-08-15)*

ISO 15190, *Medical laboratories — Requirements for safety*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN ISO 15189 and the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- IEC Electropedia: available at http://www.electropedia.org/
- ISO Online browsing platform: available at http://www.iso.org/obp

3.1
aliquot
portion of a larger amount of homogenous material, assumed to be taken with negligible sampling error

Note 1 to entry: The term is usually applied to fluids. Tissues are heterogeneous and therefore cannot be aliquoted.

Note 2 to entry: The definition is derived from References [6], [7] and [8].

[SOURCE: EN ISO 20166-3:2019, 3.1]